Hims & Hers Health, Inc. (NYSE:HIMS) receives an average “Moderate Buy” rating from brokers

Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) received an average “Moderate Buy” recommendation from the eight brokers that cover the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, and three have issued a buy rating on the company. The twelve-month average price target among brokers who have rated the stock over the past year is $8.06.

A number of research analysts have recently valued HIMS shares. SVB Leerink upgraded Hims & Hers Health from a “market performance” rating to an “outperform” rating and set a $5.00 price target for the company in a research report on Tuesday, Nov. 8. Piper Sandler raised its price target on shares of Hims & Hers Health from $6.00 to $7.00 on Tuesday in a research report. Citigroup raised its price target on shares of Hims & Hers Health from $8.00 to $9.00 in a research note on Tuesday, Nov. 15. Lastly, Bank of America upgraded Hims & Hers Health’s rating from a “neutral” rating to a “buy” rating and raised its price target for the company from $7.50 to $8.50 in a research note. Tuesday 8 November.

Healthcare stocks for him and her down 7.7%

Shares of NYSE HIMS opened at $6.10 on Friday. The stock has a market cap of $1.27 billion, a price/earnings ratio of -14.52, and a beta of 0.49. Hims & Hers Health has a 52-week low of $2.72 and a 52-week high of $7.45. The company has a 50-day moving average price of $6.11 and a 200-day moving average price of $5.79.

Hims & Hers Health (NYSE:HIMS – Get Rating) last announced its quarterly earnings results on Monday, Nov. 7. The company reported ($0.09) EPS for the quarter, topping the ($0.11) consensus estimate by $0.02. The company reported revenue of $144.84 million for the quarter, compared with analyst estimates of $130.32 million. Hims & Hers Health had a negative return on equity of 23.96% and a negative net margin of 19.34%. Equity research analysts expect Hims & Hers Health to post -0.33 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other news, director Lynne Chou O’keefe sold 10,044 shares of the company in a deal on Monday, December 19. The stock sold at an average price of $6.72, for a total transaction of $67,495.68. The transaction was disclosed in a legal filing with the SEC, which is available on the SEC’s website. In related news, insider Soleil Boughton sold 20,000 shares of the company in a deal that took place on Wednesday, Nov. 9. The shares sold at an average price of $6.00, for a total transaction of $120,000.00. Following the completion of the transaction, the insider now owns 310,271 shares of the company, valued at $1,861,626. The sale was disclosed in a filing with the Securities & Exchange Commission, accessible via the SEC’s website. Additionally, Director Lynne Chou O’keefe sold 10,044 shares of Hims & Hers Health in a deal on Monday, December 19. The shares sold at an average price of $6.72, for a total transaction of $67,495.68. Disclosure for this sale is available here. Over the past 90 days, insiders sold 79,413 shares of the company worth $470,829. Company insiders own 35.22% of the company’s shares.

Institutional trading of him and his health

Institutional investors and hedge funds have recently made changes to their positions in the company. NewView HMS SPV Partners LLC acquired a new position in Hims & Hers Health during the first quarter valued at approximately $51,506,000. State Street Corp increased its holdings of Hims & Hers Health stock by 147.8% during the second quarter. State Street Corp now owns 2,597,684 shares of the company valued at $11,768,000 after acquiring an additional 1,549,546 shares in the recent quarter. Nuveen Asset Management LLC added to its position in Hims & Hers Health by 300.2% during the third quarter. Nuveen Asset Management LLC now owns 2,001,695 shares of the company valued at $11,170,000 after purchasing an additional 1,501,568 shares during the period. Northern Trust Corp increased its holdings in Hims & Hers Health by 325.9% in the second quarter. Northern Trust Corp now owns 1,078,712 shares of the company valued at $4,886,000 after purchasing an additional 825,405 shares in the recent quarter. Finally, Renaissance Technologies LLC increased its position in Hims & Hers Health by 59.0% in the first quarter. Renaissance Technologies LLC now owns 1,682,600 shares of the company valued at $8,968,000 after purchasing an additional 624,127 shares during the period. 45.60% of the stock is currently held by institutional investors and hedge funds.

Information about his and her health

(Get Rating)

Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare providers. The company offers a range of health and wellness products and services available for purchase on its websites and mobile applications directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare professionals; and pharmaceuticals and over-the-counter devices, cosmetics and supplements, primarily focusing on wellness, sexual health and wellness, skin care and hair care.

Featured Articles

Analyst Recommendations for His and Hers Health (NYSE:HIMS)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Before considering his and her health, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and best-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks top analysts are whispering to their clients to buy now before the broader market catches on… and Hims & Hers Health wasn’t on the list.

While Hims & Hers Health currently has a “moderate buy” rating among analysts, senior analysts believe these five stocks are better buys.

View the five titles here

A beginner's guide to hedging stock investments

Leave a Comment

Your email address will not be published. Required fields are marked *